Single-cell genomics (SCG) is a fast growing and now increasingly more established approach in which genomic technologies (i.e., that assess nucleic acids such as DNA or RNA) are applied at the level of single-cells, rather than at the level of an entire cell population.
The fourth edition of this report reviews the market size, segmentation, growth and trends of the SCG market. We assess the SCG market across 7 segments and 33 subsegments: customer (e.g., academia, biopharma, applied markets, clinical), workflow step (e.g., cell isolation, sample preparation, genomic analysis), analytical technology (e.g., PCR, qPCR, microarray, next-generation-sequencing, other), field-of-study (e.g., oncology, basic cell biology, stem cell biology, microbiology, neurology, immunology, other), application (e.g., genomic variation, subpopulation characterization, circulating tumor cells, cell differentiation / reprograming, method, other), product type (e.g., instruments, reagents) and geography (e.g., U.S., Europe, Japan, China, Asia-Pacific, ROW). For each of these segments, we provide an estimated market size and growth from 2015 to 2023, as well as key growth drivers and moderators.
We review key factors driving future growth including 1) Increasing commercial availability of new applications beyond RNA-seq, including multiomics (e.g., ATAC-seq, CITE-seq) and functional assays, 2) 10X Genomics driving additional applications on large and growing install base, 3) Large-scale, well-funded initiatives, like the Human Cell Atlas, 4) New instruments that can automate and optimize the solid tissue to cells/nuclei suspension preparation, feeding high-throughput machines. On the other hand, we discuss key factors moderating growth including 1) Challenges in data analysis and data integration as the single-cell study sizes increase and single-cell multiomics interest grows, 2) High sequencing cost relative to prior analytical technologies.
In addition, we include output from a primary research campaign across 25 single-cell researchers in academia, biopharma, and clinical settings. We capture current and anticipated spend, analyte trends (e.g., RNA, DNA, multiomics), platform acquisition trends (i.e., plans on buying additional instruments), and purchasing criteria.
